Indivior names Dr. David Wheadon as new board chair

RICHMOND, VA - Indivior PLC (LON:INDV), a pharmaceutical company specializing in treatments for substance use disorders, announced the appointment of Dr. David Wheadon as the new Chair of the Board, effective immediately. The appointment follows a structured succession process led by the Nomination Committee and Juliet Thompson, the Lead Independent (LON:IOG) Director.

Dr. Wheadon, who has served on Indivior’s Board as a Non-Executive Director since June 2024, brings a wealth of experience from his previous senior roles in global regulatory affairs, patient safety, and quality assurance at AstraZeneca (NASDAQ:AZN) Plc, and in research and advocacy at the Juvenile Diabetes Research Foundation International Inc. His extensive background also includes senior positions at the Pharmaceutical (TADAWUL:2070) Research and Manufacturers of America (PhRMA), Abbott Laboratories (NYSE:ABT), GlaxoSmithKline (NYSE:GSK) Plc, and Eli Lilly and Company (NYSE:LLY).

A graduate of Johns Hopkins University School of Medicine, Dr. Wheadon also holds an A.B. in Biology from Harvard University and completed his postdoctoral training in Psychiatry at Tufts/New England Medical (TASE:PMCN) Center. In addition to his new role at Indivior, Dr. Wheadon serves as a Non-Executive Independent Director at Sotera Health Company and Vaxart (NASDAQ:VXRT), Inc., and is a member of the Board of Trustees of Mount Sinai Health System.

Juliet Thompson expressed confidence in Dr. Wheadon’s leadership abilities, citing his valuable contributions to the Board and his extensive strategic and operational experience. In his own statement, Dr. Wheadon expressed pride in leading the Board and supporting Indivior’s mission to pioneer life-transforming treatments for opioid use disorder.

The announcement also mentioned ongoing collaboration with Oaktree Capital Management LP to appoint an additional Non-Executive Director to the Board, with an update expected soon.

This leadership change comes as Indivior continues to focus on developing medicines to treat substance use disorders, aiming to provide access to evidence-based treatments for chronic conditions and co-occurring disorders associated with substance use. The company, headquartered in Richmond, VA, operates globally with a portfolio of products available in over 30 countries.

The information in this article is based on a press release statement from Indivior PLC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.